Membranoproliferative glomerulonephritis medical therapy

Revision as of 13:49, 17 April 2018 by Anmol Pitliya (talk | contribs)
Jump to navigation Jump to search


Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis medical therapy

CDC on Membranoproliferative glomerulonephritis medical therapy

Membranoproliferative glomerulonephritis medical therapy in the news

Blogs on Membranoproliferative glomerulonephritis medical therapy

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

Medical Therapy

There are three factors to consider the treatment of membranoproliferative glomerulonephritis (MPGN):

  • Identify the underlying cause of the MPGN, (e.g. lupus, infection, disorders of the complement pathway, or ideopathic MPGN);
  • Asses the factors that predict renal prognosis (e.g. degree of proteinuria, age, comorbidities); and
  • Treat the underlying cause of the MPGN,

Treatment of the underlying cause of the MPGN

Once the underlying cause of the MPGN is identified, therapy should be targeted accordingly.

MPGN due infections should target the causative pathogen. This can include antivirals, antimicrobials and antiparasitic drugs. Immunosuppressive therapy is contraindicated and can be harmful in cases of hepatitis B or C mediated MPGN[1].

See therapy for: Hepatitis B, Hepatitis C,.....

MPGN due to an autoimmune disease should target the primary disorder and should take into consideration patients age, severity of kidney involvement, and other organ involvements.

See therapy for lupus nephritis, ideopathic cryglobulinemia, paraprotein related kidney disease, C3 glomerulonephritis....

Rituximab has been also used in cases with MPGN associated with a monoclonal gammopathy and it gave a long-lasting complete or partial remissions in 7/8 cases[2]. Also, rituximab has been shown effective in the treatment of MPGN associated with chronic lymphocytic leukemia [3].

Ideopathic MPGN: Indications for immunosuppressive therapy include:

  • nephrotic range proteinuria, a
  • reduced estimated glomerular filtration,
  • and/or severe histologic changes on renal biopsy (eg, crescents)

Treatment of ideopathic MPGN includes (xxx)

with immunosuppressive drugs

With all the above treatment, Blood pressure, eGFR, proteinuria, and hematuria should be carefully monitored as a tool to check response to therapy. Follow up biopsy may be done in select case to evaluate for response, prognosis, and transformation of disease (e.g change in lupus nephritis class)

Assessment of the factors that predict renal prognosis:

In general, non-nephrotic range proteinuria (less than 3.5 g/day) and lack of nephrotic syndrome (no hypoalbuminemia, no hyperlipidemia), normal serum creatinine/GFR, and normal blood pressure are all associated with a better prognosis. Poor prognostic signs at presentation include evidence of nephrotic and nephritic syndrome, including elevated serum creatinine, hypertension plus hematuria. Bad prognosis is also associated with Idiopathic MPGN and signs of tubulointerstitial disease (interstitial inflammation, fibrosis, and tubular atrophy) which correspond to great glomerular damage.


References

  1. Sandri AM, Elewa U, Poterucha JJ, Fervenza FC (2011). "Treatment of hepatitis C-mediated glomerular disease". Nephron Clin Pract. 119 (2): c121–9, discussion c129-30. doi:10.1159/000325220. PMID 21757949.
  2. Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP; et al. (2011). "Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab". Clin J Am Soc Nephrol. 6 (7): 1609–16. doi:10.2215/CJN.10611110. PMID 21700823.
  3. Bartel C, Obermüller N, Rummel MJ, Geiger H, Hauser IA (2008). "Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine". Clin Nephrol. 69 (4): 285–9. PMID 18397703.

Template:WH Template:WS